Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary of Edinburgh, Edinburgh, UK.
Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK.
BMJ Case Rep. 2021 Nov 9;14(11):e246425. doi: 10.1136/bcr-2021-246425.
Subacute thyroiditis following vaccination is an uncommon presentation of thyrotoxicosis. As the world undertakes its largest immunisation campaign to date in an attempt to protect the population from COVID-19 infections, an increasing number of rare post vaccine side effects are being observed. We report a case of a middle-aged woman who presented with painful thyroid swelling following the second dose of the COVID-19 mRNA vaccine BNT162b2 (Pfizer-BioNTech) with clinical, biochemical and imaging features consistent with destructive thyrotoxicosis. Symptomatic management only was required for the self-limiting episode. Thyroiditis typically has a mild and self-limiting course and thus this observation should not deter people from vaccination, as COVID-19 infection has a far greater morbidity and mortality risk than thyroiditis.
接种疫苗后发生亚急性甲状腺炎是甲状腺毒症的一种罕见表现。随着全球开展迄今为止最大规模的免疫接种活动以试图保护人群免受 COVID-19 感染,越来越多的罕见疫苗接种后副作用被观察到。我们报告了 1 例中年女性在接种第二剂 COVID-19 mRNA 疫苗 BNT162b2(辉瑞-生物科技)后出现甲状腺肿痛的病例,其临床、生化和影像学特征与破坏性甲状腺毒症一致。自限性发作仅需对症治疗。甲状腺炎通常具有轻度和自限性病程,因此这种观察结果不应阻止人们接种疫苗,因为 COVID-19 感染的发病率和死亡率风险远远大于甲状腺炎。